<DOC>
	<DOCNO>NCT02403674</DOCNO>
	<brief_summary>The purpose study compare antiretroviral activity MK-1439A , single-tablet , once-daily ( q.d . ) fixed-dose combination ( FDC ) contain MK-1439 100 mg + lamivudine 300 mg + tenofovir disoproxil fumarate 300 mg , ATRIPLA™ , single-tablet FDC contain efavirenz 600 mg + emtricitabine 200 mg + tenofovir disoproxil fumarate 300 mg , treatment-naive participant infect HIV . The primary hypothesis MK-1439A q.d . non-inferior ATRIPLA™ q.d . assess proportion participant HIV-1 ribonucleic acid ( RNA ) &lt; 50 copies/mL ( Abbott RealTime HIV-1 Assay ) Week 48 .</brief_summary>
	<brief_title>Comparison MK-1439A ATRIPLA™ Treatment-Naive Human Immunodeficiency Virus ( HIV ) -Infected Participants ( MK-1439A-021 )</brief_title>
	<detailed_description />
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<mesh_term>Efavirenz , Emtricitabine , Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
	<criteria>Is HIV1 positive determine positive result enzymeimmunoassay , screen plasma HIV1 RNA ( determined central laboratory ) ≥1000 copies/mL within 45 day prior treatment phase study , HIV treatment indicate base physician assessment Has never receive antiretroviral therapy ( ART ) Is highly unlikely either become pregnant impregnate partner Has history current evidence condition , therapy , laboratory abnormality , circumstance might confound result study Is user recreational illicit drug recent history alcohol/drug abuse Has treat viral infection HIV1 ( e.g. , hepatitis B ) agent active HIV1 Has participate study investigational drug/device within 30 day prior Screening Has use systemic immunosuppressive therapy immune modulators within 30 day prior treatment study anticipate need course study Has current ( active ) diagnosis acute hepatitis due cause ( note : participant chronic hepatitis B C may enter study long fulfill entry criterion , stable liver function test , significant impairment hepatic synthetic function ) Is female pregnant , breastfeeding , expect conceive Is female expect donate egg male expect donate sperm ( investigator provide appropriate guidance regard egg and/or sperm donation completion study treatment regimen ) Has evidence decompensated liver disease manifest presence history ascites , esophageal gastric variceal bleeding , hepatic encephalopathy sign symptom advance liver disease , liver cirrhosis ChildPugh Class C score PughTurcotte ( CPT ) score &gt; 9</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>